ReviewTherapeutic advances in drug safety2025
Safety profiles of the new target therapies-pemigatinib, futibatinib, and ivosidenib-for the treatment of cholangiocarcinoma: a systematic review.
Giulia Matranga et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.